Table 1 Articles included in the review
Article first author + year | Type of study | n Patients | Age range | n test group | Characteristics test group | n control group | Characteristics control group | Type of antineoplastic therapy |
|---|---|---|---|---|---|---|---|---|
Anirudhan 2008 [29] | Retrospective study | 70 |  < 15 years | 70 | Patients with leukemia | - | - | MCP-841 protocol: Induction (Vincristine, Daunorubicin, L-Asparaginase, Prednisolone, Methotrexate); Induction 2 (6-Mercaptopurine, Cyclophosphamide, Methotrexate); Consolidation (Cyclophosphamide, Vincristine, Cytarabine, 6-Mercaptopurine, Prednisone); Maintenance (Vincristine, Daunorubicin, L-Asparaginase, Methotrexate, 6-Mercaptopurine) |
Bardellini 2017 [30] | Case report | 1 | 16 years | 1 | Stage 3 Burkitt’s lymphoma | - | - | Chemotherapy (5 days combination of Vincristine, Methotrexate, Ifosfamide, Cytarabine and Etoposide) |
Costa 2020 [31] | Cohort study | 26 | 4–18 years | 26 | Patients that have not started the chemotherapy at base-line period | - | - | Chemotherapy (not specified protocols) |
De Oliveira 2019 [32] | Case series study | 9 | 2–14 years |  | Diagnosis of ALL | - | - | GBTLI ALL 2009 protocol: combination of Dexametasone, Vincristin, Daunomycin, intrathecal chemotherapy (methotrexate, cytarabine and dexamethasone), L-Asparaginase, 6-Mercaptopurine, Cytarabine, Leucovorin, Methotrexate |
Gandhi 2017 [33] | Cohort study | 62 | 1–14 years |  | Pediatric oncological patients | - | - | Chemotherapy (not specified protocols) |
Juarez-Lopez 2018 [34] | Case control study | 103 | 4–15 years | 73 | Chemotherapy | 30 | No chemotherapy | Chemotherapy (Methotrexate, Vinblastine e Vincristine, Bleomycin) |
Levy-Polack 1998 [35] | Case control study | 96 | 1–16 years | 36 | Preventive protocol of mucositis | 60 | No preventive protocol of mucositis | Chemotherapy (not specified protocols) |
Mendonca 2012 [36] | Cohort study | 71 | 3–276 months | 71 | Diagnosis of pediatric ALL | - | - | Induction phase with MADIT (prednisone, vincristine, doxorubicin, L-asparaginase, Methotrexate, ara-C and dexamethasone). Consolidation phase with cyclophosphamide, cytarabine and 6-mercaptopurine. Intensification phase with methotrexate, 6-mercaptopurine and MADIT |
Olczak-Kowalczyk 2012 [37] | Case control study | 45 | 1,5–18 years | 20(A) + 14(B) | Organ recipients (A) + antitumor chemotherapy (B) | 11 | Group without secondary immunodeficiency | Group A immunosoppressive treatment (steroids, cyclosporine, tacrolimus, sirolimus). Group B followed protocols for each tumor: MB protocol (isophosphosphamide, eto- poside, cisplatin, vincristine, carboplatin); COPADM protocol (cyclophosphamide, vincristine, prednisone, adriamycin, methotrexate); SIOPEL protocol (cisplatin, doxorubicin) |
Pinto 2018 [38] | Retrospective trasversal study | 71 | 1–16 years | 71 | Patients with ALL undergoing chemotherapy | - | - | Chemotherapy (not specified protocols) |
Sixou 1998 [39] | Case control study | 32 | 3–16 years | 16 | Patients with cancer undergoing first treatment | 16 | Absence of general and oral pathology | FRALLE 93 Protocol: combination of Prednisolone, Daunorubicin, Vincristine, L-Asparaginase, Methotrexate, Cytarabine, Hydrocortisone, Etoposide, 6-Thioguanine, 6-Mercaptopurine, Doxorubicin, Dexemethasone, Vindesine LAME 91 Protocol: combination of Cytarabine, Mitoxantrone, Etoposide, Daunorubicin, Asparaginase, Amsacrine, intrathecal Cytarabine, Methotrexate and steroid, 6-mercaptopurine) LMB 89 Protocol: combination of Vincristine, Cyclophosphamide, Prednisone, Methotrexate, Adriamycin |
Soares 2011 [40] | Cohort study | 17 | 2–12 years | - | Patients with cancer undergoing chemotherapy | - | - | Chemotherapy (not specified protocols) |
Ye 2013 [41] | Case control study | 75 | 4–18 years | 37 | Pediatric oncological patients | 38 | Pediatric healty population | Chemotherapy (not specified protocols) |